Tigecyclin versus levofloxacin v léčbě komunitně získané pneumonie

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F08%3A00016118" target="_blank" >RIV/00843989:_____/08:00016118 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

Popis výsledku v původním jazyce

Tigecycline (TGC), a first-in-class glycylcycline that has been approved for treating complicated skin and skin structure infections and complicated intra-abdominal infections, has an expanded spectrum of activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria, including resistant strains. The purpose of this study was to compare the efficacy and safety of TGC with levofloxacin (LEV) in adult hospitalised patients with community-acquired pneumonia (CAP) in a randomised, doubleblind, phase 3 multinational trial. Hospitalised patients from 53 centres in 18 countries received 7-14 days of i.v. TGC (100-mg loading dose followed by 50 mg every 12 hours) or i.v. LEV (500 mg once or twice daily). Both regimens were generally well tolerated with only a few patients being withdrawn from the study because of any adverse event (3; 1.6% TGC versus 2, 1.1% LEV). The authors concluded that TGC was safe and efficacious in patients hospitalised with CAP, achieving similar effic

Název v anglickém jazyce

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

Popis výsledku anglicky

Tigecycline (TGC), a first-in-class glycylcycline that has been approved for treating complicated skin and skin structure infections and complicated intra-abdominal infections, has an expanded spectrum of activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria, including resistant strains. The purpose of this study was to compare the efficacy and safety of TGC with levofloxacin (LEV) in adult hospitalised patients with community-acquired pneumonia (CAP) in a randomised, doubleblind, phase 3 multinational trial. Hospitalised patients from 53 centres in 18 countries received 7-14 days of i.v. TGC (100-mg loading dose followed by 50 mg every 12 hours) or i.v. LEV (500 mg once or twice daily). Both regimens were generally well tolerated with only a few patients being withdrawn from the study because of any adverse event (3; 1.6% TGC versus 2, 1.1% LEV). The authors concluded that TGC was safe and efficacious in patients hospitalised with CAP, achieving similar effic

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Chemotherapy

ISSN

1120-009X

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

Suppl.1

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000261742400004

EID výsledku v databázi Scopus

—